METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY

Targeted drugs are recommended for treatment of metastatic colorectal cancer. Second and further lines therapy options include anti-EGFR therapy, eligible for patients with wild-type KRAS (cetuximab and panitumumab), and relatively new drug — regorafenib, which could be used for all patients.The aim...

Full description

Saved in:

Bibliographic Details
Main Authors:	N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2016-09-01
Series:	Фармакоэкономика
Subjects:	metastatic colorectal cancer targeted drugs regorafenib cetuximab panitumumab
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/146
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
by: Maria Ignez Freitas Melro Braghiroli, et al.
Published: (2024-01-01)

The efficacy of regorafenib monotherapy as the third-and later-line treatment for metastatic colorectal cancer: a retrospective study
by: An Tianqi, et al.
Published: (2022-08-01)

Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trialResearch in context
by: Arndt Stahler, et al.
Published: (2025-01-01)

Real-world treatment patterns and outcomes among patients initiating sequential regorafenib and trifluridine/tipiracil ± bevacizumab in patients with metastatic colorectal cancer in a US community setting (SEQRT2)
by: Tanios Bekaii-Saab, et al.
Published: (2025-06-01)

The impact of combining cetuximab with the traditional chemotherapy regimens on clinical effectiveness in metastatic colorectal cancer: a systematic review and meta-analysis
by: Marryam Azeem, et al.
Published: (2025-02-01)

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
by: Carlo Signorelli, et al.
Published: (2024-12-01)

The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies
by: Fan Yang, et al.
Published: (2025-05-01)

Safety and efficacy of encorafenib–cetuximab combination in BRAFV600E-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study
by: A. Fernández-Montes, et al.
Published: (2024-09-01)

Beyond efficacy parity: a novel cost-equilibrium framework for value assessment of competing third-line therapies in metastatic colorectal cancer
by: Shunlong Ou, et al.
Published: (2025-08-01)

Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping
by: J. Sgouros, et al.
Published: (2025-03-01)

Aphthous-Like Stomatitis in a Patient Receiving Panitumumab
by: Maria Kouri, et al.
Published: (2024-12-01)

miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer
by: Shiyun Chen, et al.
Published: (2025-05-01)

Prolonged Survival Outcome in a Patient with Refractory Metastatic Colorectal Cancer Treated with Regorafenib Plus 5-Fluorouracil: A Case Report and Literature Review
by: Abdullah Esmail, et al.
Published: (2025-04-01)

Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report
by: Ahmad KH Ibrahimi, et al.
Published: (2023-06-01)

Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma
by: Wen-Chen Tang, et al.
Published: (2023-07-01)

Uso de regorafenibe em pacientes com câncer colorretal metastático previamente tratados com bevacizumabe ou aflibercepte: experiência clínica uni-institucional
by: Rodrigo Nogueira Fogace, et al.
Published: (2017-10-01)

Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment
by: Khadijeh Falahzadeh, et al.
Published: (2024-09-01)

Excellent response of cetuximab plus chemotherapy after pembrolizumab monotherapy in metastatic hypopharyngeal cancer: A case report
by: Anh Tuan Pham, et al.
Published: (2025-03-01)

Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids
by: Giulia Agostini, et al.
Published: (2025-07-01)

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers
by: Ana Fernández Montes, et al.
Published: (2019-03-01)

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation
by: N. N. Babyshkina, et al.
Published: (2022-11-01)

Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
by: Celso Abdon Lopes de Mello, et al.
Published: (2022-12-01)

Modern strategy of metastatic colorectal cancer treatment (literature review)
by: O. I. Kit, et al.
Published: (2024-09-01)

Applications and perspectives of metastatic colorectal cancer organoids
by: CUI Jingwei, et al.
Published: (2024-06-01)

How opportune is multigene testing in metastatic colorectal cancer? A review
by: Cristina Orlov-Slavu, et al.
Published: (2021-10-01)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
by: Andrea S. Fung, et al.
Published: (2020-07-01)

Targeted therapy acts to sensitize stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer
by: Xiye Sun, et al.
Published: (2025-05-01)

Treatment sequencing in metastatic colorectal cancer
by: Nanteznta Torounidou, et al.
Published: (2025-01-01)

Effcacy and toxicity of regorafenib compared to reintrodaction of chemotherapy in metastatic colon cancer: retrospective multicenter study
by: E. S. Kuzmina, et al.
Published: (2023-09-01)

Case Report: A case of interstitial pneumonia in a colorectal cancer patient with a history of lung cancer treated with cetuximab
by: Yang Yang, et al.
Published: (2025-07-01)

Safety and Efficacy of Regorafenib and 5-Fluorouracil Combination Therapy in Refractory Metastatic Colorectal Cancer After Third-Line Treatment: An Institutional Experience
by: Maen Abdelrahim, et al.
Published: (2025-05-01)

Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis
by: Shaoqing Fan, et al.
Published: (2025-04-01)

THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE
by: M. I. Sluzhev, et al.
Published: (2021-10-01)

Molecular symphonies and signalling pathways orchestrated by the gut microbiome in metastatic colorectal cancer (mCRC); a state-of-the-art review
by: Nayeralsadat Fatemi, et al.
Published: (2024-01-01)

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab
by: Toru Imai, et al.
Published: (2024-12-01)

Ongoing 5-year+ survival after multiple metastasectomies, followed by CAPOX plus bevacizumab, for metastatic colorectal cancer
by: Kozue Matsuishi, et al.
Published: (2020-06-01)

Consensus Statements for Clinical Practice in Advanced/Metastatic Colorectal Cancers in India Using a Modified Delphi Method
by: Anant Ramaswamy, et al.

The trends and hotspots of immunotherapy for metastatic colorectal cancer from 2013 to 2022: A bibliometric and visual analysis
by: Yifan Gong, et al.
Published: (2024-12-01)

A PET-CT radiomics model for immunotherapy response and prognosis prediction in patients with metastatic colorectal cancer
by: Wenbiao Chen, et al.
Published: (2025-05-01)

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
by: Yanrong Wang, et al.
Published: (2025-03-01)